Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors

Aligning Patient and Provider Goals

Released On
October 22, 2021

Expires On
October 22, 2022

Media Type

Completion Time
30 minutes

Hematology-Oncology, Neonatology

Leukemia, Oncology

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC, working in collaboration with the CLL Society (CLLS) and the Leukemia & Lymphoma Society (LLS).


Supported by educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company; and Janssen Biotech, Inc.

Credit Available

  • Physicians — Enduring activity: maximum of 0.5 AMA PRA Category 1 Credit(s)
  • Nurses — Enduring activity: 0.5 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Access Activity Series: Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors


Target Audience

The intended audience for this activity are hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies
  • List the emerging combination regimens, including BTK inhibitors
  • Discuss recent and new data supporting the role of BTK inhibitors in r/r CLL
  • Integrate patient perspectives and priorities into comprehensive care-team management of CLL


Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Director of Clinical Research, Division of Lymphoma
Harvard Medical School
Dana-Farber Cancer Institute

Susan M. O’Brien, MD

Associate Director for Clinical Sciences
Chao Family Comprehensive Cancer Center
Medical Director, Sue & Ralph Stern Center for
Clinical Trials and ResearchChao Family Endowed Chair for Cancer Clinical Science
Division of Hematology/Oncology, School of Medicine
University of California Irvine

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nurse Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Matthew S. Davids, MD, MMSc

  • Consulting Fees (e.g., advisory boards): AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Eli Lilly, Genentech, Janssen, Merck, Pharmacyclics LLC, Research to Practice, Takeda, TG Therapeutics, Verastem, Zentalis
  • Contracted Research: Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem

Susan M. O’Brien, MD

  • Consulting Fees (e.g., advisory boards): AbbVie, Alexion, Amgen, Aptose Biosciences Inc., Astellas, Autolus, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Gilead, GlaxoSmithKline, Janssen Oncology, Johnson and Johnson, Juno Therapeutics, Merck, NOVA Research Company, Pharmacyclics LLC, Pfizer, Sunesis, TG Therapeutics, Vaniam Group LLC, Verastem, Vida Ventures
  • Contracted Research: Acerta, Caribou, Kite, Gilead, Pharmacyclics LLC, Pfizer, Regeneron, Sunesis, TG Therapeutics

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Tariqa Ackbarali, Medical Director PlatformQ Health Education, LLC: nothing to disclose.

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unapproved/Off Label Use (if applicable)

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in this activity. To participate in the activity, go to To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

Hardware/Software Requirements

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at

Technical Support:
For any technical issues or issues with your CME Certificate, please contact at 1-877-394-1306 or

PlatformQ Health Privacy Policy:

By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here describes (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.

Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.

In plain English, here is what we affirm:

  • You can change your registration profile at any time from our “Profile” page
  • To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at
  • You can end your association with PlatformQ Health at any time
  • PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
  • EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting with the subject line “Data Request”

You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: